Search results for "Kinetic"

showing 10 items of 3064 documents

Adverse drug reactions in the oral cavity

2012

Several drugs may have a number of adverse reactions (ADRs) involving the oro-facial region. The dose of the drug and the time required for the reaction to take place are relevant parameters; nonetheless, ADRs mechanisms are not always known and ADRs are not always predictable since aspects other than drug pharmacodynamics and/or pharmacokinetics, as well as various interacting variables contribute to the final outcome. All tissues and many functions of the oral cavity can be affected. In particular, salivary function is fre- quently involved and hypo-salivation is the main manifestation; several mucosal lesions with different morphology (ulcerations, vesiculo- bullous lesions, white lesion…

Drugdrug pharmacodynamicosteonecrosimedicine.medical_specialtyTime FactorsDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjectSettore MED/50 - Scienze Tecniche Mediche Applicatehypo-salivationPigmentationsPharmacologyOral cavitymucosal lesionDrug withdrawalPharmacokineticsSettore MED/28 - Malattie OdontostomatologicheDrug DiscoveryHumansMedicinemedical liabilityDrug reactionpharmacokineticmedia_commonPharmacologyMouthDose-Response Relationship Drugbusiness.industrybisphosphonates.Mucosal lesionsMouth MucosadrugAdverse reactionmedicine.diseaseDermatologyPharmaceutical PreparationsTastePharmacodynamicsoral cavityadverse drug reaction oral cavityMouth DiseasesSalivationbusiness
researchProduct

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Metformin Hydrochloride.

2021

Abstract Data are examined regarding possible waiver of in vivo bioequivalence testing (i.e. biowaiver) for approval of metformin hydrochloride (metformin) immediate-release solid oral dosage forms. Data include metformin's Biopharmaceutics Classification System (BCS) properties, including potential excipient interactions. Metformin is a prototypical transporter-mediated drug and is highly soluble, but only 50% of an orally administered dose is absorbed from the gut. Therefore, metformin is a BCS Class III substance. A BCS-based approval approach for major changes to marketed products and new generics is admissible if test and reference dosage forms have the identical active pharmaceutical …

Drugendocrine system diseasesmedia_common.quotation_subjectPharmaceutical ScienceExcipientAdministration OralBiological Availabilitytransporters02 engineering and technologyPharmacologyBioequivalence030226 pharmacology & pharmacyDosage formPermeabilityBiopharmaceutics03 medical and health sciencesMetformin hydrochloride0302 clinical medicinePharmacokineticsmedicineBiopharmaceutics Classification System (BCS)media_commonActive ingredientDosage FormsbioequivalenceexcipientsChemistry021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystembiowaiverMetforminMetforminSolubilityTherapeutic Equivalencyregulatory science0210 nano-technologypharmacokineticsmedicine.drugJournal of pharmaceutical sciences
researchProduct

Use of ICS/LABA (extra-fine and non-extra-fine) in elderly asthmatics.

2016

Age represents an exclusion criterion in randomized clinical trials designed to test the efficacy and safety of inhaled drugs in asthma. As a consequence, data on efficacy and safety of inhaled corticosteroid (ICS) and long-acting β2 agonist (LABA) combinations in elderly asthmatics are scanty. Older age is associated with an increased proportion of comorbid conditions; in addition, all organ functions undergo a process of senescence, thus reducing their ability to metabolize the agents. Overall, these age-associated conditions may variably, and often unpredictably, affect the metabolism and excretion of respiratory drugs. However, pharmacological treatment of asthma does not follow specifi…

Druglong-acting β2 agonistmedicine.medical_specialtyasthma treatmentmedia_common.quotation_subjectPopulationReviewSettore MED/10 - Malattie Dell'Apparato Respiratorio030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialPharmacokineticsInhaled corticosteroidlawmedicinePharmacology (medical)General Pharmacology Toxicology and PharmaceuticseducationAdverse effectIntensive care medicineAsthmamedia_commoneducation.field_of_studyChemical Health and SafetyInhalationbusiness.industryaginglung functionGeneral Medicinemedicine.diseasecomorbidity030228 respiratory systemAnesthesiaPharmacodynamicslong-acting β2 agonistsinhaled corticosteroidsbusinessSafety ResearchTherapeutics and clinical risk management
researchProduct

The Biopharmaceutics Classification System: Subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC

2013

The Biopharmaceutics Classification System (BCS) has found widespread utility in drug discovery, product development and drug product regulatory sciences. The classification scheme captures the two most significant factors influencing oral drug absorption; solubility and intestinal permeability and it has proven to be a very useful and a widely accepted starting point for drug product development and drug product regulation. The mechanistic base of the BCS approach has, no doubt, contributed to its wide spread acceptance and utility. Nevertheless, underneath the simplicity of BCS are many detailed complexities, both in vitro and in vivo which must be evaluated and investigated for any given…

Drugmedia_common.quotation_subjectAdministration OralPharmaceutical ScienceComputational biologyPharmacologyModels BiologicalPermeabilityArticleIntestinal absorptionQuality by DesignDosage formBiopharmaceuticsIVIVCIn vivoTerminology as TopicAnimalsHumansTechnology PharmaceuticalComputer SimulationPharmacokineticsIntestinal Mucosamedia_commonChemistryBiopharmaceuticsReproducibility of ResultsHydrogen-Ion ConcentrationBiopharmaceutics Classification SystemIntestinal AbsorptionPharmaceutical PreparationsSolubilityEuropean Journal of Pharmaceutical Sciences
researchProduct

Interpretation of Ocular Melanin Drug Binding Assays. Alternatives to the Model of Multiple Classes of Independent Sites

2016

Melanin has a high binding affinity for a wide range of drugs. The determination of the melanin binding capacity and its binding affinity are important, e.g., in the determination of the ocular drug distribution, the prediction of drug effects in the eye, and the trans-scleral drug delivery. The binding parameters estimated from a given data set vary significantly when using different isotherms or different nonlinear fitting methods. In this work, the commonly used bi-Langmuir isotherm, which assumes two classes of independent sites, is confronted with the Sips isotherm. Direct, log-log, and Scatchard plots are used, and the interpretation of the binding curves in the latter is critically a…

Drugmedia_common.quotation_subjectBinding energyPharmaceutical Science02 engineering and technology010402 general chemistryBioinformatics01 natural sciencesInterpretation (model theory)MelaninGoodness of fitMelanin bindingFitting methodsDrug Discoverymedia_commonMelaninsScatchard plotChemistrytechnology industry and agricultureChloroquineModels Theoretical021001 nanoscience & nanotechnology0104 chemical sciencesKineticsBiophysicsMolecular Medicine0210 nano-technologyMetoprololMolecular Pharmaceutics
researchProduct

Microseparation techniques for the study of the enantioselectivity of drug-plasma protein binding.

2009

Stereoselectivity in protein binding can have a significant effect on the pharmacokinetic and pharmacodynamic properties of chiral drugs. The investigation of enantioselectivity of drugs in their binding with human plasma proteins and the identification of the molecular mechanisms involved in the stereodiscrimination by the proteins represent a great challenge for clinical pharmacology. In this review, the separation techniques used for enantioselective protein binding experiments are described and compared. An overview of studies on enantiomer–protein interactions, enantiomer–enantiomer interactions as well as chiral drug–drug interactions, including allosteric effects, is presented. The c…

Drugmedia_common.quotation_subjectClinical BiochemistryAllosteric regulationPlasma protein bindingBiochemistryChromatography AffinityAnalytical ChemistryPharmacokineticsSpecies SpecificityDrug DiscoveryHumansAnimal speciesMolecular Biologymedia_commonPharmacologyChromatographyChemistryEnantioselective synthesisElectrophoresis CapillaryStereoisomerismGeneral MedicineBlood ProteinsBlood proteinsPharmaceutical PreparationsChromatography GelStereoselectivityAllosteric SiteProtein BindingBiomedical chromatography : BMC
researchProduct

Differential interactions of the broad spectrum drugs artemisinin, dihydroartemisinin and artesunate with serum albumin

2013

Artemisinin is a drug, widely used in malaria treatment. As the binding affinity of artemisinin and its derivatives dihydroartemisinin and artesunate to blood serum proteins might influence the effectiveness of the drug, binding of artemisinin and derivatives to serum albumin was studied under near physiological conditions. Binding kinetics indicate a simple, single-step association process for all artemisinin derivatives. The determined changes in enthalpy and entropy upon drug binding clearly indicate that hydrophobic forces are most important for artemisinin and dihydroartemisinin binding, whereas binding of artesunate is governed by both hydrophilic and hydrophobic forces. Key residues,…

Drugmedia_common.quotation_subjectmedicine.medical_treatmentSerum albuminArtesunatePharmaceutical ScienceDihydroartemisininPharmacologyHydrophobic effectchemistry.chemical_compoundBlood serumparasitic diseasesDrug DiscoverymedicineAnimalsArtemisininSerum Albuminmedia_commonPharmacologybiologyChemistryArtemisininsReceptor–ligand kineticsMalariaComplementary and alternative medicineBiochemistryArtesunatebiology.proteinMolecular MedicineCattleDrug Therapy CombinationHydrophobic and Hydrophilic InteractionsProtein Bindingmedicine.drugPhytomedicine
researchProduct

Induction of Drug Transporters Alters Disposition of Risperidone - A Study in Mice

2010

Pharmacokinetic interactions, e.g. modulation of drug transporters like P-glycoprotein at the blood-brain barrier, can be a reason for treatment non-response. This study focuses on the influence of induction of drug transporters on the disposition of the antipsychotic drugs risperidone and 9-hydroxyrisperidone. Brain and serum concentrations of risperidone and its active metabolite 9-hydroxyrisperidone, which are known P-glycoprotein substrates, were measured after drug transporter induction with rifampicin, dexamethasone or 5-pregnene-3beta-ol-20-on-16alpha-carbonitrile using high performance liquid chromatography. Disposition of risperidone and 9-hydroxyrisperidone was dramatically decrea…

Drugmedia_common.quotation_subjectmedicine.medical_treatmentlcsh:RS1-441Pharmaceutical ScienceP-glycoproteinPharmacologyArticlelcsh:Pharmacy and materia medicaPharmacokineticsMedicineAntipsychoticDexamethasoneActive metaboliteP-glycoproteinmedia_commonrisperidoneRisperidonebiologybusiness.industryTransporterdrug transporterantipsychoticsdispositionbiology.protein9-hydroxyrisperidonebusinessmedicine.drugPharmaceutics
researchProduct

Interactions and Monitoring of Antipsychotic Drugs

2012

As a consequence of individualized antipsychotic pharmacotherapy, many patients need more than a single drug, since they do not respond sufficiently to monotherapy. Other patients suffer from comorbid diseases and therefore require additional drugs from other pharmacological classes. Drug combinations, however, can give rise to pharmacokinetic and/or pharmacodynamic drug–drug interactions. Evaluation of pharmacokinetic interactions with antipsychotic drugs must consider substrate, inhibitor, and inducer properties for the cytochrome P450 (CYP) isoenzymes of all combined drugs. For consideration of pharmacodynamic interactions, special attention must be given to effects on dopamine D2, hista…

Drugmedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentmedia_common.quotation_subjectPharmacologyPharmacotherapyPharmacokineticsExtrapyramidal symptomsTherapeutic drug monitoringPharmacodynamicsDopamine receptor D2Medicinemedicine.symptombusinessAntipsychoticmedia_common
researchProduct

Pharmacokinetic rationale for switching from donepezil to galantamine.

2001

Galantamine, the most recently approved acetylcholinesterase inhibitor (AChEI) for use in the United States, has allosteric modulating activity at nicotinic receptors and inhibits acetylcholinesterase. This dual mechanism of action may make galantamine an attractive option for patients with Alzheimer's disease who have not benefited from their current therapy; thus, methods for switching patients from donepezil or rivastigmine to galantamine are needed. Protocols for switching patients from one AChEI to another must consider both the time required for washout of the first drug and the rate of dose escalation of the second drug. Both issues depend on the pharmacodynamics, pharmacokinetics, a…

Drugmedicine.drug_classmedia_common.quotation_subjectPharmacologyModels Biologicalchemistry.chemical_compoundPharmacokineticsPiperidinesAlzheimer DiseaseGalantamineMedicineHumansPharmacology (medical)DonepezilDonepezilmedia_commonAgedPharmacologyRivastigminebusiness.industryGalantamineAcetylcholinesterasechemistryAcetylcholinesterase inhibitorPharmacodynamicsIndansCholinesterase Inhibitorsbusinessmedicine.drugClinical therapeutics
researchProduct